Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508532 · ClinicalTrials.gov registry record · Phase 1
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT02508532 is a Phase 1 study that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 250 participants.
The verdict
NCT02508532, a Phase 1 study, has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
Interventions
- DRUG Avapritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-08 |
| Est. Completion | 2021-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02508532
The ClinicalTrials.gov registry entry for NCT02508532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avapritinib is the first listed.
NCT02508532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02508532 about?
NCT02508532 is a clinical study titled "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors". This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or...
What is the current status of trial NCT02508532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2015-08. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT02508532?
The interventions under investigation include: Avapritinib (DRUG).
Who is sponsoring clinical trial NCT02508532?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.